Cosmos Health Inc. is a diversified, vertically integrated global healthcare group that owns proprietary pharmaceutical and nutraceutical brands, manufactures and distributes generic and innovative medicines, produces biocides and medical devices, develops drug repurposing solutions and operates a telehealth platform.
The company generates revenue from the sale of generic pharmaceuticals, nutraceutical supplements, biocide products, oncology drug candidates, licensing of…
Cosmos Health Inc. is a diversified, vertically integrated global healthcare group that owns proprietary pharmaceutical and nutraceutical brands, manufactures and distributes generic and innovative medicines, produces biocides and medical devices, develops drug repurposing solutions and operates a telehealth platform.
The company generates revenue from the sale of generic pharmaceuticals, nutraceutical supplements, biocide products, oncology drug candidates, licensing of its AI driven drug repurposing platform, telehealth subscriptions and contract manufacturing for third parties.
The company operates through the following segments: Generic Medicines, Nutraceuticals, Biocides, Novel Oncology Drugs, Drug Repurposing, Telehealth Services.
- Generic Medicines: Develops, manufactures and sells generic pharmaceutical products such as ASTO‑CHOL, Diorium, HEART‑FREE, LIPICHOL, Miltus, Newzypra, PNEUMO‑KAST, Sahar, VIVALCID and Diabit‑is in tablets, capsules, liquids, ointments and creams.
- Nutraceuticals: Offers the Sky Premium Life® and Mediterranation® brands with approximately 165 SKUs covering vitamins, minerals, amino acids, herbal extracts for wellbeing, immunity, cardiovascular health, bones and joints, men’s and women’s health, beauty, digestive health, brain function, energy, mood, stress and sleep.
- Biocides: Provides the C‑Sept® and C‑Scrub® brands, which combine chlorhexidine digluconate with isopropyl alcohol to deliver broad spectrum antimicrobial and antiseptic formulations for infection control.
- Novel Oncology Drugs: Focuses on repurposed and innovative anticancer therapies targeting CNS, prostate, ovarian and colorectal cancers, including the obesity‑related compound CCX0722, a MALT1‑targeting agent for CNS cancer and TADs derivatives with multi targeted activity against resistant tumor cells.
- Drug Repurposing: Operates the Cloudscreen® AI platform that analyzes proteomic and variomic data to identify new therapeutic uses for existing drugs, with patent applications filed for multiple sclerosis, glioma and hematologic malignancies.
- Telehealth Services: Delivers the ZipDoctor platform, a direct to consumer subscription service providing 24/7 access to board certified physicians and licensed mental‑health counsellors via telephone or secured video chat in the United States with English and Spanish coverage.
Cosmos Health Inc. competes in highly regulated generic pharmaceutical, nutraceutical, biocide, oncology and telehealth markets against large pharmaceutical companies, generic manufacturers, nutraceutical retailers, biocide suppliers, oncology drug developers and telemedicine providers; its competitive advantages stem from vertical integration, proprietary brands, an AI driven repurposing platform, GMP and EMA manufacturing licenses, a broad product portfolio and the ability to launch new generic equivalents quickly.
The company serves retail pharmacies, hospitals, private clinics, wholesalers and governmental agencies across the European Union, the United Kingdom, the United Arab Emirates and increasingly North America, with no single customer accounting for 10% or more of its total consolidated revenue.